Scarica l'app Stockscreener
4.01
6.08%
0.23
Pre-mercato:
4.09
0.08
+2.00%
Aquestive Therapeutics Inc Borsa (AQST) Ultime notizie
Aquestive Therapeutics prices $85 million public offering By Investing.com - Investing.com Canada
Aquestive Therapeutics Secures $75 Million Funding Agreement with RTW - MarketScreener
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock - GlobeNewswire
Aquestive Secures $85M Backing to Launch Novel Sublingual Film for Severe Allergic Reactions - Stock Titan
First-Ever Oral Emergency Allergy Treatment Gets $75M Boost from RTW Investment - Stock Titan
Aquestive Therapeutics Inc. Forms Bullish Flag — Upside AheadTrend Reversal & Scalable Portfolio Growth Ideas - 선데이타임즈
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q2 2025 Earnings Call Transcript - Insider Monkey
Aquestive Therapeutics Inc (AQST) Q2 2025 Earnings Call Highlights: Navigating Revenue ... By GuruFocus - Investing.com Canada
Aquestive Therapeutics Inc. Rebound Backed by Sentiment ShiftJuly 2025 Intraday Action & High Accuracy Swing Trade Signals - 선데이타임즈
Aquestive Therapeutics Reports Q2 2025 Financial Results - TipRanks
Aquestive Therapeutics Q2 2025 Earnings: What to Expect - AInvest
Aquestive's Q2 2025 Earnings Call: Navigating Contradictions in FDA Approval, Launch Readiness, and Market Strategy - AInvest
Aquestive Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:AQST) - Seeking Alpha
Transcript : Aquestive Therapeutics, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Earnings call transcript: Aquestive Therapeutics Q2 2025 sees EPS beat, revenue miss - Investing.com UK
Aquestive Therapeutics Q2 2023 Earnings Report & AnalysisNews and Statistics - IndexBox
Aquestive 2025 Q2 Earnings Net Loss Widens Sharply - AInvest
Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates - MSN
Aquestive Therapeutics: Q2 Earnings Snapshot - Stamford Advocate
Aquestive Therapeutics Q2 Earnings Miss Estimates, Revenue Down 50% YoY - AInvest
Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Aquestive Therapeutics shares rise 2.33% after-hours after FDA accepts NDA submission for Anaphylm™. - AInvest
Aquestive Therapeutics: Positioning for a Game-Changing 2026 Launch of Anaphylm - AInvest
Aquestive Q2 2025 slides: Anaphylm advances toward FDA decision, cash burn continues By Investing.com - Investing.com South Africa
Aquestive Q2 2025 slides: Anaphylm advances toward FDA decision, cash burn continues - Investing.com
Aquestive Therapeutics earnings beat by $0.03, revenue fell short of estimates - Investing.com Canada
AQSTAquestive Therapeutics Latest Stock News & Market Updates - Stock Titan
Aquestive Therapeutics Inc (AQST) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Aquestive Therapeutics Inc Q2 2025 Earnings Preview: Revenue Expectations Fall to $11.32M, Earnings at -$0.17 per Share - AInvest
Aquestive Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Uncovering Potential: Aquestive Therapeutics's Earnings Preview - 富途牛牛
Aquestive Therapeutics Inc (AQST) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
What caused AQST's surprising Q2 2024 EPS surge? - AInvest
Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET - The Manila Times
Aquestive Therapeutics Q2 2025 Earnings Release Date Set for August 11 | AQST Stock News - Stock Titan
Why is Aquestive Therapeutics Inc. stock attracting strong analyst attentionInvest confidently with real-time data analysis - Jammu Links News
What is the risk reward ratio of investing in Aquestive Therapeutics Inc. stockTrack top-performing stocks in real-time - Jammu Links News
What makes Aquestive Therapeutics Inc. stock price move sharplyAccelerated investment success - Jammu Links News
How does Aquestive Therapeutics Inc. compare to its industry peersCapitalize on market momentum for maximum gains - Jammu Links News
What institutional investors are buying Aquestive Therapeutics Inc. stockDiscover breakthrough investment opportunities - Jammu Links News
What drives Aquestive Therapeutics Inc. stock priceCapitalize on market momentum for maximum gains - Jammu Links News
What is the dividend policy of Aquestive Therapeutics Inc. stockInvest confidently with data-driven strategies - Jammu Links News
What analysts say about Aquestive Therapeutics Inc. stockMaximize your portfolio’s growth potential - Jammu Links News
How strong is Aquestive Therapeutics Inc. company’s balance sheetExceptional market performance - Jammu Links News
What are the latest earnings results for Aquestive Therapeutics Inc.Unlock powerful stock screening tools today - Jammu Links News
What are Aquestive Therapeutics Inc. company’s key revenue driversCapitalize on emerging investment opportunities - Jammu Links News
What are the technical indicators suggesting about Aquestive Therapeutics Inc.Unlock powerful market trend analysis - Jammu Links News
Should I hold or sell Aquestive Therapeutics Inc. stock in 2025Significant capital appreciation - Jammu Links News
Aquestive Therapeutics Faces Regulatory Challenges with '5050Item' - AInvest
Is Aquestive Therapeutics Inc. stock overvalued or undervaluedPost Market Guidance For Smart Trading - Jammu Links News
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 39% Share Price Surge Not Quite Adding Up - 富途牛牛
Aquestive Therapeutics Faces Potential Risks with ‘5050Item’: What Investors Need to Know - TipRanks
Investors Hope for Bounce in Aquestive Therapeutics Inc. After SelloffAI Based High Gain Watchlist Scanner Shared - beatles.ru
Strategies to average down on Aquestive Therapeutics Inc.Stock Selection With High Accuracy Based on Models - metal.it
4.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):